Medically reviewed by Jay N. Yepuri, MD PBC is a chronic liver disease that damages bile ducts and can lead to liver failure. You can get treatment for PBC to slow disease progression and manage ...

Ipsen’s elafibranor has shown promise as a treatment for primary sclerosing cholangitis (PSC), a rare liver disease that currently has no approved treatment options. Results from the phase 2 ELMWOOD ...

PARIS, FRANCE, 24 April 2025 Ipsen (Euronext: IPN; ADR: IPSEY) will be presenting data from the late-breaking abstract on elafibranor in the investigational Phase II ELMWOOD study at the European ...

Swedish researchers have discovered a new test which can detect risk of liver disease years before symptoms typically appear.

Freddie Bentley has revealed he was diagnosed with liver failure aged 24 after he was rushed to hospital with yellow pupils ...

Ipsen’s Iqirvo (elafibranor) has been recommended by the National Institute for Health and Care Excellence (NICE) to treat adults with the rare liver disease primary biliary cholangitis (PBC). The ...

Research from earlier this year found that 80 per cent of England’s regional health bodies lacked an effective pathway to ...

The Friends of the PBC Foundation hosted their first U.S.-based PBC Patient Conference, bringing together patients, families, ...

The liver donors and recipients involved in Utah's first pediatric paired liver exchange met for the first time on Friday.

– New findings to be presented at the 2025 European Association for the Study of the Liver (EASL) Congress continue to demonstrate the effectiveness of Livdelzi (seladelpar) in reducing pruritus in ...

MORRISTOWN, N.J., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a wholly owned biopharmaceutical subsidiary of Alfasigma S.p.A., today announced its decision to voluntarily ...

Dublin, June 04, 2025 (GLOBE NEWSWIRE) -- The "Primary Biliary Cholangitis Market Opportunities and Strategies to 2034" report has been added to ResearchAndMarkets.com's offering. This report ...